medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2012, Number 3

Next >>

Rev Mex Urol 2012; 72 (3)

Nitric oxide synthase: a study of its expression as a molecular marker in relation to prostate cancer

Floriano-Sánchez E, Cárdenas-Rodríguez N, Castro-Marín M, López-Silvestre JC, Zapata-Villalba MÁ, Campos-Salcedo JG, Estrada-Carrasco CE, Mendoza Álvarez LA, Martínez-Juarez NE, Paredes-Calva C, Sedano-Lozano A

Language: Spanish
References: 37
Page: 103-107
PDF size: 330.22 Kb.


ABSTRACT

Background: A descriptive, comparative, prospective study was carried out to observe neuronal nitric oxide synthase (nNOS) expression in prostate tissue presenting with cancer and hyperplasia.
Methods: Tissue samples were taken from patients diagnosed with benign prostatic hyperplasia and prostate cancer within the time frame of 2005 to 2009. The samples were stored in the Pathology Department of the Hospital Central Militar, according to department inclusion, exclusion and elimination criteria.
Results and Conclusions: Relative density was obtained through immunohistochemistry and a reduction of nNOS was observed in tissues with prostate cancer when compared with its expression in tissues with benign prostatic hyperplasia (BPH).


REFERENCES

  1. Khan Ma, Partin Aw. Partin Tables: Past and present. BJU Int 2003;92(1):7-11.

  2. Tanagho EA, Mc Aninch JW. Urología general de Smith. 13a Edición. México. Manual Moderno. 2005. 364-368.

  3. Ahmed MM, Lee CT, Oesterling JE. Current trend in the epidemiology of prostatic disease: benign hyperplasia and adenocarcinoma. In: Naz RK (Editor). Prostate: basic and clinical aspects. Boca Raton, Florida. Crc Press. 1997. 3-25.

  4. Carlson BC. Embriología humana y biología del desarrollo. 3ra edición. España. Ed. Elsevier. 2005. 393-419.

  5. Fulton D, Gratton JP, Mccabe TJ, et al. Regulation of endotelium-derived nitric oxide production by the protein kinasa akt. Nature 1999;399(6736):597-601.

  6. Sagars Gk, Ayala Ag, Von Eschenbach AC, et al. The prognostic importance of gleason grade in prostatic adenocarcinoma. A long-term follow-up study of 648 patients. Int J Radiat Oncol Biol Phys 199515;31(2):237-245.

  7. American Urological Association. The Management of Benign Prostatic Hyperplasia. In: PRODOGY Guidance Prostate - Benign Hyperplasia October 2004. 2a Edition. Baltimore. American Urological Association, Inc. 2003.34.

  8. Wilt Tj, Howe Rw, Rutks Ir, et al. Terazosina para la hiperplasia prostática benigna (Revisión Cochrane Traducida). Cochrane database of systematic reviews 2011;5: CD001042. DOI: 10.1002/14651858. CD001042

  9. Cockett LC, Cussenot A, Griffiths K, et al. Regulacion of Prostate Grown. In: Chatelain C, Denis L, Foo KT, et al (editors). Proceedings of the fifth internacional consultation on benign prostatic hyperplasia. United Kingdom. Health Publication Ltd. 2001. 79 -106.

  10. Guess H. Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev 1992;14:131-153.

  11. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2003;361(9366):1359-1367.

  12. Consultado el 21 de mayo de 2012. http://www.cochrane.ihcai.org/ programa_seguridad_paciente_costa_rica/pdfs/36_Tratamiento-dela-Hiperplasia-Prostatica-Benigna.pdf

  13. Consultado el 21 de mayo de 2012. Http://Www.Update-Software.Com

  14. Consultado el 21 de mayo de 2012. http://www.cvsp.cucs.udg.mx/guias/TODAS/IMSS_176_09_HIPERPLASIA_PROSTATICA/IMSS_176_09_EyR.pdf

  15. Gonzalgo ML, Isaacs WB. Molecular pathways to prostate cancer. J Urol 2003;170(6 Pt 1):2444-2452.

  16. Riggs JE. Longitudinal Gompertzian analysis of prostate cancer mortality in the U.S., 1962-1987: a method of demonstrating relative environmental, genetic and competitive influences upon mortality. Mech Ageing Dev 1991;60(3):243-253.

  17. National Cancer Institute. PRODOGY Guidance Prostate - Benign Hyperplasia October 2004. 2a Edition. USA. Ed. McGrawh-Hill. 2003. 584-594.

  18. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000;14(19):2410-2434.

  19. Macdonald NJ, Steeg Ps. Molecular basis of tumor metastasis. Cancer Surv 1993;16:175-199.

  20. Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 2003;16(2):95-101.

  21. Crawford ED, DeAntoni EP, Ross CA. The role of prostate-specific antigen in the chemoprevention of prostate cancer. J Cell Biochem Suppl 1996;25:149-155.

  22. Mills CD, Shearer J, Evans R, et al. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J Immunol 1992;149(8):2709-2714.

  23. Barry M. Epidemiology and natural history of benign prostatic hyperplasia. In: Chisolm G (Editor). Handbook of Benign Prostatic Hyperplasia. New York, USA. Raven Press. 1994. 1-18.

  24. Hall SE, Holman CD, Wisniewski ZS, et al. Prostate cancer: socioeconomic, geographical and private-health insurance effects on care and survival. BJU Int 2005;95(1):51-58.

  25. Roehrbon CG, Mc Connell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED, et al (editors). Campbell´S Urology. 8th Ed. Philadelphia. W.B. Saunders Co. 2002. 12970-13300.

  26. Moodley YP. The role of inducible nitric oxide in health and disease. Current Diagnostic Pathology 2002;8(5):297-304.

  27. Pacheco R, Rodríguez P, López C, et al. Expresión de las sintasas de óxido nítrico en tumores glómicos de cabeza y cuello. Rev Sanid Milit Mex 2006;60(6):369-378.

  28. Crowell JA, Steele VE. Is inducible oxide synthase a target for chomoprevention. Mol Cancer Ther 2003;2(8):815-823.

  29. Krinski B, Yu B. Mechanism of action of biological antioxidants. Proc Soc Exp Biol Med 1992;200(2):248-254.

  30. Olivares C, Guzmán G, Medina Nr, et al. Especies reactivas Del Oxígeno (Eros): Bioquímica Inorgánica Y Biomedicina. En: Hicks JJ (editor). Bioquímica. 2da Ed. México. Mcgraw-Hill. 2006. 690-708.

  31. McCord JM. Evolution of free radicals and oxidative stress. Am J Med 2000;108(8):652-659.

  32. Jakus V. The role of free radicals, Oxidative stress and antioxidant systems in diabetic vascular disease. Bratisl Lek Listy 2000;101(10):541-551.

  33. Tenorio L, Fermín A, Torres N, et al. Del el óxido nítrico y las enfermedades cardiovasculares: cardioprotección versus cardiotoxicidad. Revista Mexicana De Ciencias Farmacéuticas 2008;3:38-48.

  34. Consultado el 21 de mayo de 2012. http./www.inegi.org.mx.

  35. Renaudin K, Denis MG, Karam G, et al. Loss of Nos1 Expression in High-Grade Renal Cell Carcinoma Associated With a Shift of No Signaling. Br J Cancer 2004;90(12):2364-2369.

  36. Wen Y, Perez EJ, Green PS, et al. NNOS is Involved in Estrogen Mediated Neuroprotection in Neuroblastomacells, Neuropharmacology and Neurotoxicology. Neuroreport 2004;15(9):1515-1518.

  37. Carrizo PH, Dubin M, Stopanni M, et al. Fisiopatológicos del Óxido Nítrico y su Relación con el Estrés Oxidativo. Medicina 1998;58(4):376-373.




2020     |     www.medigraphic.com